Tempus to Participate in the Stifel 2025 Healthcare Conference
Get Alerts TEM Hot Sheet
Join SI Premium – FREE
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13 in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:00 AM ET.
The live webcast will be available through the events page of Tempus’ Investor Relations website or by clicking the following link: https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/n5gWXXPJwMBQmjZjJYHqKv
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028098887/en/
Tempus Communications
Erin Carron
[email protected]
Tempus Investor Relations
Elizabeth Krutoholow
[email protected]
Source: Tempus AI, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AM Best Upgrades Issuer Credit Rating of Dunav-Re a.d.o
- Alts Custodian Launches Private Markets Portfolio Construction and Modeling Platform
- AI Agents Are Advancing Faster Than Enterprise Data Is Ready for Them
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Stifel, James Beeland Rogers Jr.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share